Evidence map›Paper›PMID 42759890›Full record

ArticleNeuroscience research2026

Plasma metabolomic and lipidomic profiling in early-stage psychosis.

Shuji Kawaguchi, Kazuhiro Sonomura, Koko Ishizuka, Fumihiko Matsuda, Akira Sawa, Kun Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuji KawaguchiCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address: shuji@genome.med.kyoto-u.ac.jp.
Kazuhiro SonomuraTechnology Research Laboratory, Shimadzu Corporation, Nakagyo-ku, Kyoto, 604-8511, Japan.
Koko IshizukaDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fumihiko MatsudaCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.
Akira SawaDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Departemtn of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Departments of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kun YangDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kunyang@jhmi.edu.

Funding

Project 3P50MH094268 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SAWA, AKIRA · 2011 to 2020
$19.9M
Project 3P50MH136297 · NIMH · JOHNS HOPKINS UNIVERSITY · PI ANDREW P LANE · 2024 to 2026
$12.8M
High throughput marker for cognitive deficit: cellular autofluorescenceR01MH107730 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SAWA, AKIRA · 2018 to 2022
$3.0M
NIMH NIH HHS P50 MH094268NIMH NIH HHS P50 MH136297NIMH NIH HHS R01 MH107730
6 · The paper itself

Abstract

Metabolic alterations in early-stage psychosis may provide insights into disease pathophysiology and potential biomarkers. We performed targeted metabolomic and lipidomic profiling of plasma samples from 31 patients with early-stage psychosis (onset within 24 months) and 22 healthy controls using a liquid chromatography-mass spectrometry (LC-MS) platform. Of 523 compounds analyzed, 16 (3 metabolites, 13 lipids) were significantly altered in patients compared with controls, with a significant enrichment of glycerolipids (69%). Within patients, glycerolipids significantly correlated with symptom severity and cognitive performance. These findings highlight the involvement of glycerolipid metabolism in early psychosis and clinical outcomes.

Indexed as

Psychotic DisordersAdultBiomarkersFemaleHumansLipidomicsLipidsLiquid Chromatography-Mass SpectrometryMaleMetabolomicsSchizophreniaYoung AdultBiomarkersLipidsBiomarkersGlycerolipidsLipidomicsLiquid chromatography-mass spectrometryMetabolomicsPsychosisSchizophrenia

Identifiers

PMID42759890
PMCPMC13689022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.